Biotech Values

[DewDiligence]

VRUS does yet another financing—the second one in the past 3 months:

http://finance.yahoo.com/news/Pharmasset-Announces-Proposed-prnews-340200996.html?x=0&.v=1

Assuming the underwriter’s overallotment is exercised, the offering will be 3.7M shares, an expansion of about 12% in shares outstanding.

There have been rumors that VRUS’ BoD was trying to sell the company; however, the new financing, which raises money VRUS does not actually need, would seem to refute those rumors.